Barbara Seliger

Summary

Affiliation: Martin Luther University
Country: Germany

Publications

  1. ncbi Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  2. ncbi Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma
    Barbara Seliger
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Halle, Germany
    J Transl Med 7:90. 2009
  3. ncbi Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany
    Proteomics 11:2528-41. 2011
  4. ncbi Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors
    Barbara Seliger
    Martin Luther Universitaet Halle Wittenberg, Institute of Medical Immunology, 06112 Halle Saale, Germany
    Trends Mol Med 16:184-92. 2010
  5. ncbi Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Magdeburger Str 2, 06112 Halle, Germany
    Cancer Immunol Immunother 59:529-40. 2010
  6. ncbi Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma
    Barbara Seliger
    Johannes Gutenberg University Mainz, 3rd Department of Internal Medicine, Mainz, Germany
    Proteomics 5:2631-40. 2005
  7. ncbi Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University, Halle, Germany
    Int J Cancer 118:129-38. 2006
  8. ncbi Different regulation of MHC class I antigen processing components in human tumors
    Barbara Seliger
    Martin Luther Universitat Halle Wittenberg, Institute of Medical Immunology, Halle Saale, Germany
    J Immunotoxicol 5:361-7. 2008
  9. ncbi Strategies of tumor immune evasion
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany
    BioDrugs 19:347-54. 2005
  10. ncbi Candidate biomarkers in renal cell carcinoma
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany
    Proteomics 7:4601-12. 2007

Detail Information

Publications79

  1. ncbi Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  2. ncbi Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma
    Barbara Seliger
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Halle, Germany
    J Transl Med 7:90. 2009
    ..Aberrant expression of UCHL1 has been found in a number of human solid tumors including renal cell carcinoma (RCC). In RCC, UCHL1 overexpression is associated with tumor progression and an altered von Hippel Lindau gene expression...
  3. ncbi Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany
    Proteomics 11:2528-41. 2011
    ..Thus, this experimental strategy might be suited to define potential candidate biomarkers and novel targets for T-cell-based immunotherapies of this disease...
  4. ncbi Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors
    Barbara Seliger
    Martin Luther Universitaet Halle Wittenberg, Institute of Medical Immunology, 06112 Halle Saale, Germany
    Trends Mol Med 16:184-92. 2010
    ....
  5. ncbi Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Magdeburger Str 2, 06112 Halle, Germany
    Cancer Immunol Immunother 59:529-40. 2010
    ..Our results suggest that HLA class I APM component abnormalities are mainly due to regulatory mechanisms, play a role in the clinical course of prostate cancer and on the outcome of T cell-based immunotherapies...
  6. ncbi Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma
    Barbara Seliger
    Johannes Gutenberg University Mainz, 3rd Department of Internal Medicine, Mainz, Germany
    Proteomics 5:2631-40. 2005
    ..These include members of the fatty acid binding protein family, which have the potential to serve as diagnostic or prognostic markers for the screening of RCC patients...
  7. ncbi Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University, Halle, Germany
    Int J Cancer 118:129-38. 2006
    ..These investigations may eventually lead to the development of effective immunotherapies to control viral infections and virus-associated malignant diseases...
  8. ncbi Different regulation of MHC class I antigen processing components in human tumors
    Barbara Seliger
    Martin Luther Universitat Halle Wittenberg, Institute of Medical Immunology, Halle Saale, Germany
    J Immunotoxicol 5:361-7. 2008
    ....
  9. ncbi Strategies of tumor immune evasion
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany
    BioDrugs 19:347-54. 2005
    ..Both host- and tumor-related mechanisms can lead to a failure to mount a proper anti-tumor-specific immune response, and these are frequently key factors in limiting the success of cancer immunotherapy...
  10. ncbi Candidate biomarkers in renal cell carcinoma
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany
    Proteomics 7:4601-12. 2007
    ..Despite the low number of validated differentially expressed proteins some of them might serve as candidate biomarkers for the diagnosis and/or as therapeutic targets...
  11. ncbi Structure, expression and function of HLA-G in renal cell carcinoma
    Barbara Seliger
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Magdeburger Strasse 2, 06112 Halle, Germany
    Semin Cancer Biol 17:444-50. 2007
    ..Thus, HLA-G represents one important immune escape mechanism of human RCC which has an impact on the design of T and NK cell-based immunotherapies in this disease...
  12. ncbi The complex role of B7 molecules in tumor immunology
    Barbara Seliger
    Martin Luther University, Institute of Medical Immunology, 06112 Halle, Germany
    Trends Mol Med 14:550-9. 2008
    ..We also discuss recent therapeutic strategies that aim to improve immune-cell recognition of tumors and induce tolerance to autoreactive immune responses in normal tissues by manipulating B7 functions...
  13. ncbi Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma?
    Barbara Seliger
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, 06112 Halle Saale, Germany
    J Proteome Res 10:191-9. 2011
    ....
  14. ncbi Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany
    Clin Cancer Res 13:27-37. 2007
    ..Due to the currently inefficient therapies and the low 5-year survival rates of RCC patients, novel diagnostic, prognostic, and therapeutic markers are urgently needed for this disease...
  15. ncbi Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma
    Barbara Seliger
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Halle, Germany
    Proteomics 9:1567-81. 2009
    ....
  16. ncbi Molecular mechanisms of MHC class I abnormalities and APM components in human tumors
    Barbara Seliger
    Martin Luther Universitat Halle Wittenberg, Institute of Medical Immunology, Magdeburger Str 2, 06112 Halle Saale, Germany
    Cancer Immunol Immunother 57:1719-26. 2008
    ..This review will give an overview of the underlying molecular mechanisms of MHC class I abnormalities in human tumors of distinct histology, which also might have an impact on the design of T cell-based immunotherapies...
  17. ncbi Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?
    Derek Atkins
    IIIrd Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany
    J Urol 171:885-9. 2004
    ....
  18. ncbi Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response
    Jürgen Bukur
    Third Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany
    Hum Immunol 64:1081-92. 2003
    ....
  19. ncbi Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy
    Barbara Seliger
    The Johannes Gutenberg University, IIIrd Department of Internal Medicine, Mainz, Germany
    Proteomics 3:979-90. 2003
    ..In conclusion, conventional proteome analysis as well as PROTEOMEX could be successfully employed for the identification of markers which may allow the selection of patients prior to specific immunotherapy...
  20. ncbi Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation
    Barbara Seliger
    Johannes Gutenberg University, 3rd Department of Internal Medicine, D 55101 Mainz, Germany
    Clin Cancer Res 9:1721-7. 2003
    ..These data suggest that TAP defects in RCC lesions are caused by regulatory abnormalities. Therefore, T-cell-based immunotherapy may benefit from the administration of cytokines that up-regulate TAP expression...
  21. ncbi Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome
    Markus Meissner
    Department of Internal Medicine, Johannes Gutenberg-University, Mainz, Germany
    Clin Cancer Res 11:2552-60. 2005
    ..CONCLUSIONS: Our results suggest that the analysis of APM component expression in HNSCC lesions can provide useful prognostic information in patients with HNSCC...
  22. ncbi Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma
    Isabelle Hodson
    Third Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany
    Int J Oncol 23:991-9. 2003
    ..3% heterozygosity independent of a particular allele. Thus, TAP2 gene polymorphism is not linked to renal cell carcinoma since no association between a particular amino acid residue and the disease was found...
  23. ncbi Systematic comparative protein expression profiling of clear cell renal cell carcinoma: a pilot study based on the separation of tissue specimens by two-dimensional gel electrophoresis
    Rudolf Lichtenfels
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, 06112 Halle Saale, Germany
    Mol Cell Proteomics 8:2827-42. 2009
    ....
  24. ncbi Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines
    Annedore Respa
    Martin Luther Universitat Halle Wittenberg, Institute of Medical Immunology, Halle, Saale, Germany
    Clin Cancer Res 17:2668-78. 2011
    ..Hence, we analyzed whether there exists a link between the IFN-γ signaling pathway, constitutive HLA class I APM component expression, and IFN-γ resistance...
  25. ncbi MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma
    Derek Atkins
    Johannes Gutenberg University, Third Department of Internal Medicine, Mainz, Germany
    Int J Cancer 109:265-73. 2004
    ..These findings support the hypothesis that Ki-ras mutations may contribute to immune escape mechanisms of tumors by downregulating the MHC class I APM component expression...
  26. ncbi Comparative expression profiling of distinct T cell subsets undergoing oxidative stress
    Rudolf Lichtenfels
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany
    PLoS ONE 7:e41345. 2012
    ....
  27. ncbi Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma
    Rudolf Lichtenfels
    IIIrd Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany
    Proteomics 2:561-70. 2002
    ..These data suggest that HSP play a role in the immunogenicity of RCC and thus might be used for the design of immunization strategies to induce a potent antitumor response in this disease...
  28. ncbi Identification of E2F1 as an important transcription factor for the regulation of tapasin expression
    Juergen Bukur
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, 06112 Halle, Saale, Germany
    J Biol Chem 285:30419-26. 2010
    ....
  29. ncbi Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma
    Esther Kamphausen
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Magdeburger Str 2, 06112, Halle Saale, Germany
    Cancer Immunol Immunother 59:1273-84. 2010
    ....
  30. ncbi HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties
    Christian V Recktenwald
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, 06112 Halle Saale, Germany
    J Biol Chem 287:24320-9. 2012
    ..Thus, Bgn inhibits the major properties of HER-2/neu-transformed cells, which is inversely modulated by the PKC signaling cascade...
  31. ncbi HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway
    Felix Herrmann
    Third Department of Internal Medicine and Pathology, Johannes Gutenberg University, Mainz, Germany
    Cancer Res 64:215-20. 2004
    ..Thus, a functional link between deficient APM component expression and HER-2/neu overexpression is proposed that might influence the design of HER-2/neu-targeted T-cell-based immunotherapeutic strategies...
  32. ncbi Altered detoxification status and increased resistance to oxidative stress by K-ras transformation
    Christian V Recktenwald
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Halle, Germany
    Cancer Res 68:10086-93. 2008
    ..Both the enhanced resistance against xenobiotic compounds as well as an altered oxidative pathway might confer growth advantages for tumor cells carrying dominant-positive K-ras mutations such as in lung or pancreatic adenocarcinoma...
  33. ncbi B7-1 and B7-2 act differentially in the induction of a T cell response: their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy
    Kai Kronfeld
    Coordination Center for Clinical Trials (KKS) Mainz, Johannes Gutenberg University, Mainz, Germany
    Int J Cancer 117:794-9. 2005
    ..The distinct patterns of cytokine induction by B7-1 and B7-2 obviously depend on the HLA Class I compatibility. These conclusions have substantial implications for the development of B7-based vaccines used for immunotherapies...
  34. ncbi A proteomic view at T cell costimulation
    Rudolf Lichtenfels
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany
    PLoS ONE 7:e32994. 2012
    ..Data provide a detailed map of individual protein alterations at the global proteome level in response to TCR/CD28-mediated T cell activation...
  35. ncbi Heat shock proteins in renal cell carcinomas
    Derek Atkins
    IIIrd Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany
    Contrib Nephrol 148:35-56. 2005
    ..In this chapter we will briefly present the relevance of HSPs in the pathomechanisms of RCC...
  36. ncbi The role of classical and non-classical HLA class I antigens in human tumors
    Juergen Bukur
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Halle Saale, Germany
    Semin Cancer Biol 22:350-8. 2012
    ....
  37. ncbi Promoter methylation of aminopeptidase N/CD13 in malignant melanoma
    Jens Wulfänger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, 06112 Halle, Saale, Germany
    Carcinogenesis 33:781-90. 2012
    ..Thus, the heterogeneous APN expression pattern in melanoma cells is epigenetically controlled and directly associated with an altered migration capacity but not of clinical significance in our study group...
  38. ncbi Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1
    Ulrike Ritz
    Third Department of Internal Medicine, Johannes Gutenberg-University, Mainz, Germany
    J Immunol 170:941-6. 2003
    ..Thus, biochemical and functional evidence is presented that the Glu(263) of the TAP1 protein, but not the Phe(265), is critical for proper TAP function...
  39. ncbi IFN inducibility of major histocompatibility antigens in tumors
    Barbara Seliger
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Halle, Germany
    Adv Cancer Res 101:249-76. 2008
    ..Therefore, the aim of this chapter is to summarize the frequency of impaired interferon signal transduction, their underlying molecular mechanisms, and their clinical relevance...
  40. ncbi Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion
    Jens Wulfaenger
    Martin Luther University, Institute of Medical Immunology, Halle Wittenberg, Germany
    Mol Membr Biol 25:72-82. 2008
    ..Thus, high APN enzyme activity may antagonize the cellular properties regulated by the CXCR4/SDF-1alpha system in embryonic kidney cells...
  41. ncbi Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues
    Mabruk Erhuma
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Germany
    Int J Cancer 120:2393-400. 2007
    ..However, further studies are needed to provide more detailed information of the role of NEP/CD10 under physiological and pathophysiological conditions of the pancreas...
  42. ncbi Influence of Ki-ras-driven oncogenic transformation on the protein network of murine fibroblasts
    Christian V Recktenwald
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Halle, Germany
    Proteomics 7:385-98. 2007
    ..In addition, this approach allows the discovery of ras-associated cellular mechanisms, which might lead to the identification of physiological targets for pharmacological interventions of the treatment of Ki-ras-associated human tumors...
  43. ncbi Design of proteome-based studies in combination with serology for the identification of biomarkers and novel targets
    Barbara Seliger
    The Johannes Gutenberg University, IIIrd Department of Internal Medicine, Mainz, Germany
    Proteomics 2:1641-51. 2002
    ....
  44. ncbi The expression, function, and clinical relevance of B7 family members in cancer
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Magdeburger Strasse 2, Halle Saale, Germany
    Cancer Immunol Immunother 61:1327-41. 2012
    ....
  45. ncbi Novel insights into the molecular mechanisms of HLA class I abnormalities
    Barbara Seliger
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, Magdeburger Strasse 2, Halle, Saale, Germany
    Cancer Immunol Immunother 61:249-54. 2012
    ..This information will not only give novel insights into the (patho) physiology of the antigen-processing and presenting pathway, but will help in the future to design effective T cell-based immunotherapies...
  46. ncbi Monitoring peri-operative immune suppression in renal cancer patients
    Sabine Hase
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, D 06112 Halle, Germany
    Oncol Rep 25:1455-64. 2011
    ..The monocytic HLA-DR intensity represents a suitable marker for monitoring tumor stage and surgery-associated immunosuppression in RCC patients...
  47. ncbi The immunomodulatory capacity of mesenchymal stem cells
    Antje Gebler
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, 06112 Halle Saale, Germany
    Trends Mol Med 18:128-34. 2012
    ....
  48. ncbi B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response
    Dagmar Quandt
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Halle, Germany
    Clin Cancer Res 17:3100-11. 2011
    ..B7-H3 and B7-H4 have recently been described in different tumor entities but the relevance for melanoma has not yet been studied so far...
  49. ncbi HLA class I antigen abnormalities and immune escape by malignant cells
    Barbara Seliger
    Johannes Gutenberg University, III. Department of Internal Medicine, Mainz, Germany
    Semin Cancer Biol 12:3-13. 2002
  50. ncbi Cloning and functional analyses of the mouse tapasin promoter
    Felix Herrmann
    3rd Department of Internal Medicine, Johannes Gutenberg University, 55131 Mainz, Germany
    Immunogenetics 55:379-88. 2003
    ..Thus, characterization of the tapasin promoter represents the molecular basis for the understanding of the heterogeneous expression levels of tapasin under physiological and pathophysiological conditions...
  51. ncbi Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities
    Chiara Massa
    Institute of Medical Immunology, Martin Luther University Halle Wittenberg, 06112 Halle, Saale, Germany
    J Immunol 190:3328-37. 2013
    ....
  52. ncbi High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?
    Wolfgang Altermann
    Martin Luther University Halle Wittenberg, Institute of Medical Immunology, Magdeburger Strasse 2, 06112 Halle, Germany
    Nephrol Dial Transplant 22:2795-9. 2007
    ..Previous studies have suggested that the pre-transplant levels of the soluble CD30 molecule (sCD30) represent a non-invasive tool which can be used as a biomarker for the prediction of kidney allograft rejections...
  53. ncbi Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma
    Jürgen Bukur
    Third Department of Internal Medicine, Johannes Gutenberg University, 55101 Mainz, Germany
    Cancer Res 63:4107-11. 2003
    ..Thus, aberrant HLA-G expression is found at a relatively high frequency in RCC and might participate in evasion of these tumor cells from immunosurveillance...
  54. ncbi High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors
    Barbara Seliger
    Johannes Gutenberg University, Third Department of Internal Medicine, D 55101 Mainz, Germany
    Int J Oncol 20:349-53. 2002
    ....
  55. ncbi HLA-G and MIC expression in tumors and their role in anti-tumor immunity
    Barbara Seliger
    Johannes Gutenberg University, IIIrd Department of Internal Medicine, Johannes Gutenberg Universitat, Langenbeckstr 1D 55101 Mainz, Germany
    Trends Immunol 24:82-7. 2003
    ..Available data suggest that the balance between activating and suppressing signals significantly influences the efficacy of the immune response and consequently of tumor progression...
  56. ncbi 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications
    Sandra Coral
    Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy
    Clin Cancer Res 8:2690-5. 2002
    ....
  57. ncbi Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors
    Zhihai Qin
    Institute of Immunology, Universitaetsklinikum Benjamin Franklin, Haus IA, Hindenburgdamm 30, Free University of Berlin, 12200 Berlin, Germany
    Cancer Res 62:2856-60. 2002
    ..Thus, the lack of TAP1 expression did not change the immunogenicity of tumor cells. It may enable tumor cells to escape T-cell recognition during the effector phase of an antitumor immune response...
  58. ncbi The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies
    Jürgen Bukur
    Illrd Department of Internal Medicine, Johannes Gutenberg University, Langenbeckstr 1, 55101 Mainz, Germany
    Semin Cancer Biol 13:353-9. 2003
    ..Thus, aberrant HLA-G expression might participate in evasion of these tumor cells from immunosurveillance...
  59. ncbi Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas
    Isabel Maleno
    Departmento Analisis Clinicos, Hospital Universitario Virgen Nieves, Granada, Spain
    Int J Cancer 109:636-8. 2004
    ..These results might help to understand the significantly different biological behavior of both RCC subtypes...
  60. ncbi Detection of renal cell carcinoma-associated markers via proteome- and other 'ome'-based analyses
    Barbara Seliger
    Third Department of Internal Medicine at the Johannes Gutenberg University, Mainz, Germany. 3-med.klinik.uni-mainz.de
    Brief Funct Genomic Proteomic 2:194-212. 2003
    ..This review focuses on the identification of new biomarkers and therapeutic targets for renal cell carcinoma using different 'ome'-based technologies...
  61. ncbi Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells
    Walburgis Brenner
    Department of Urology, University of Mainz, D 55131 Mainz, Germany
    Int J Oncol 25:1157-63. 2004
    ..These findings provide a conceptual basis for treatment of renal cell carcinoma by interfering with tumor cell proliferation...
  62. ncbi Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer
    Ena Wang
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Res 64:7279-87. 2004
    ..Finally, a small subset of genes is associated with lineage-specific oncogenesis, and these may provide information regarding the biological behavior of RCCs and facilitate diagnostic classification of RCCs...
  63. ncbi Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1
    Yuanmei Lou
    Michael Smith Laboratories, University of British Columbia, 2185 East Mall, Vancouver, BC V6T 1Z4, Canada
    Vaccine 25:2331-9. 2007
    ....
  64. ncbi Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides
    Carmen Scheibenbogen
    Medizinische Klinik III, , Onkologie und Transfusionsmedizin, , , Berlin, Germany
    Int J Cancer 99:403-8. 2002
    ..These results suggest that peptide vaccination resulted in a prolonged relapse-free interval in these high-risk patients...
  65. ncbi Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses
    Rudolf Lichtenfels
    IIIrd Department of Internal Medicine, Johannes Gutenberg-University, Langenbeckstr. 1, D-55101 Mainz, Germany
    Biochim Biophys Acta 1646:21-31. 2003
    ..Thus, PROTEOMEX represents a valuable approach for the identification of metabolic enzymes which might be used as markers for the diagnosis of RCC...
  66. ncbi Common cancer biomarkers
    Christopher F Basil
    Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Cancer Institute, NIH, Bethesda, Maryland 20892-1184, USA
    Cancer Res 66:2953-61. 2006
    ....
  67. ncbi Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival
    Yuanmei Lou
    Michael Smith Laboratories and Biomedical Research Centre, University of British Columbia, Vancouver, Canada
    Cancer Res 65:7926-33. 2005
    ....
  68. ncbi B7/CD28 costimulation of T cells induces a distinct proteome pattern
    Kai Kronfeld
    IIIrd Department of Internal Medicine, Johannes Gutenberg University, 55131 Mainz, Germany
    Mol Cell Proteomics 4:1876-87. 2005
    ..Our results provide novel insights into the complexity of the CD28 costimulatory pathway of T cells and will help to identify potential targets of therapeutic interventions for modulating anti-tumor T cell activation...
  69. ncbi Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis
    Johannes Beckers
    GSF National Research Center for Environment and Health, Institute of Experimental Genetics, Neuherberg, Germany
    Int J Cancer 114:590-7. 2005
    ..Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html.)..
  70. ncbi Targeting of tumor associated antigens in renal cell carcinoma using proteome-based analysis and their clinical significance
    Roland Kellner
    Merck, Darmstadt, Germany
    Proteomics 2:1743-51. 2002
    ..In conclusion, PROTEOMEX could be employed for the identification of tumor-associated antigens of the cytoskeleton which are differentially expressed in RCC of distinct subtypes as well as in normal renal epithelium...
  71. ncbi Tuning tumor-specific T-cell activation: a matter of costimulation?
    Hinrich Abken
    Tumorgenetik, Klinik I fur Innere Medizin, Universitat zu Koln, D 50931 Köln, Germany
    Trends Immunol 23:240-5. 2002
  72. ncbi Tumors as elusive targets of T-cell-based active immunotherapy
    Francesco M Marincola
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Trends Immunol 24:335-42. 2003
    ..Furthermore, we will discuss the information still required in order to understand the mechanism(s) governing tumor rejection by the immune system in response to TA-specific immunization...
  73. ncbi Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity
    Kerstin Herzer
    Division of Immunogenetics, German Cancer Research Center DKFZ, D 69120 Heidelberg, Germany
    J Virol 77:8299-309. 2003
    ..These results demonstrate a way in which HCV avoids recognition by NK cells that may contribute to the establishment of a chronic infection...
  74. ncbi A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells
    Zhihai Qin
    Institute of Immunology, University Clinic Benjamin Franklin, Free University of Berlin, 12200 Berlin, Germany
    Cancer Res 63:4095-100. 2003
    ..Taken together with our previous findings, we conclude that IFN-gamma-dependent antiangiogenesis is a general mechanism involved in tumor rejection by CD4(+) and CD8(+) T-cell effectors...
  75. ncbi Functional cysteine-less subunits of the transporter associated with antigen processing (TAP1 and TAP2) by de novo gene assembly
    Susanne Heintke
    Institut fur Biochemie, Biozentrum, Johann Wolfgang Goethe Universitat Frankfurt, Marie Curie Str 9, D 60439, Frankfurt M, Germany
    FEBS Lett 533:42-6. 2003
    ..Cysteine-less TAP1 and TAP2 restore maturation and intracellular trafficking of MHC class I molecules to the cell surface...
  76. ncbi Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission
    Ilka B Schiffer
    Institute of Toxicology, Johannes Gutenberg University of Mainz, Obere Zahlbacherstrasse 67, 55131 Mainz, Germany
    Cancer Res 63:7221-31. 2003
    ..Tumor remission was dependent on the volume of the tumors before down-regulation of HER-2/neu...
  77. ncbi Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines
    Aniruddha Choudhury
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 108:71-7. 2004
    ..Our results suggest that siRNA may be an effective method of abrogating the effect of HER2 in tumorigenesis...
  78. ncbi Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity
    Håkan Norell
    Department of Oncology and Pathology, Immune and Gene Therapy Laboratory, Cancer Center Karolinska, Karolinska Institutet, Karolinska University Hospital, Sweden
    Cancer Res 66:6387-94. 2006
    ..Abnormalities in HLA class I antigen expression are common features during the progression of ovarian cancer, and haplotype loss was, for the first time, described as an underlying mechanism...
  79. ncbi High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma
    Norbert Meidenbauer
    Department of Hematology/Oncology, University of Regensburg, Regensburg, Germany
    Cancer Res 64:6319-26. 2004
    ..Immunotherapeutic approaches should not only focus on the induction of a robust antitumor immune response, but should also have to target tumor immune escape mechanisms...